GB201908453D0 - Compounds for treating respiratory disease - Google Patents

Compounds for treating respiratory disease

Info

Publication number
GB201908453D0
GB201908453D0 GBGB1908453.2A GB201908453A GB201908453D0 GB 201908453 D0 GB201908453 D0 GB 201908453D0 GB 201908453 A GB201908453 A GB 201908453A GB 201908453 D0 GB201908453 D0 GB 201908453D0
Authority
GB
United Kingdom
Prior art keywords
compounds
respiratory disease
treating respiratory
treating
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1908453.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enterprise Therapeutics Ltd
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Priority to GBGB1908453.2A priority Critical patent/GB201908453D0/en
Publication of GB201908453D0 publication Critical patent/GB201908453D0/en
Priority to CN202080043484.1A priority patent/CN114269433A/zh
Priority to PCT/GB2020/051414 priority patent/WO2020249956A1/fr
Priority to JP2021573749A priority patent/JP2022535986A/ja
Priority to EP20734265.0A priority patent/EP3983069A1/fr
Priority to US17/547,967 priority patent/US20220098164A1/en
Ceased legal-status Critical Current

Links

GBGB1908453.2A 2019-06-12 2019-06-12 Compounds for treating respiratory disease Ceased GB201908453D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1908453.2A GB201908453D0 (en) 2019-06-12 2019-06-12 Compounds for treating respiratory disease
CN202080043484.1A CN114269433A (zh) 2019-06-12 2020-06-12 用于治疗呼吸系统疾病的tmem16a的调节剂
PCT/GB2020/051414 WO2020249956A1 (fr) 2019-06-12 2020-06-12 Modulateurs de tmem16a pour le traitement d'une maladie respiratoire
JP2021573749A JP2022535986A (ja) 2019-06-12 2020-06-12 呼吸器の疾患を処置するためのｔｍｅｍ１６ａのモジュレータ
EP20734265.0A EP3983069A1 (fr) 2019-06-12 2020-06-12 Modulateurs de tmem16a pour le traitement d'une maladie respiratoire
US17/547,967 US20220098164A1 (en) 2019-06-12 2021-12-10 Modulators of tmem16a for treating respiratory disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1908453.2A GB201908453D0 (en) 2019-06-12 2019-06-12 Compounds for treating respiratory disease

Publications (1)

Publication Number Publication Date
GB201908453D0 true GB201908453D0 (en) 2019-07-24

Family

ID=67386340

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1908453.2A Ceased GB201908453D0 (en) 2019-06-12 2019-06-12 Compounds for treating respiratory disease

Country Status (6)

Country Link
US (1) US20220098164A1 (fr)
EP (1) EP3983069A1 (fr)
JP (1) JP2022535986A (fr)
CN (1) CN114269433A (fr)
GB (1) GB201908453D0 (fr)
WO (1) WO2020249956A1 (fr)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
GB9515975D0 (en) * 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
EP1032265B1 (fr) * 1997-11-20 2003-10-29 Cerus Corporation Composes de psoralene utilises pour inactiver des agents pathogenes
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
EP1368323B1 (fr) * 2001-02-14 2010-06-30 Warner-Lambert Company LLC Pyrimidine comme inhibiteurs de la m talloprot inase de matrice
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
DE10160357A1 (de) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
DE10251019A1 (de) * 2002-11-02 2004-05-19 Aventis Pharma Deutschland Gmbh Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen
DE10300017A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Selektive MMP 13 Inhibitoren
US20050004111A1 (en) * 2003-01-03 2005-01-06 Aventis Pharma Deutschland Gmbh Selective MMP-13 inhibitors
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
CA2635580A1 (fr) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals Holding, Inc. Inhibiteurs de metalloproteases a base de bisamides substitues
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
WO2010022355A1 (fr) * 2008-08-21 2010-02-25 Purdue Research Foundation Composés et procédés pour le traitement des maladies respiratoires
FR2958849A1 (fr) * 2010-04-14 2011-10-21 Boiron Medicament homeopathique a activite anti-cancereuse
CN107441097A (zh) * 2010-04-16 2017-12-08 阿西纳斯公司 用于预防和治疗癌症的组合物以及方法
US9302991B2 (en) * 2010-10-18 2016-04-05 Raqualia Pharma Inc. Arylamide derivatives as TTX-S blockers
MX2014013734A (es) * 2012-05-11 2015-06-10 Abbvie Inc Inhibidores de nampt.
US9505743B2 (en) * 2012-10-15 2016-11-29 Aquilus Pharmaceuticals, Inc. Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
US20160152579A1 (en) * 2013-07-11 2016-06-02 Servicio Andaluz De Salud Oxazolidinone derivatives as ppar ligands
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
US11572347B2 (en) * 2017-10-20 2023-02-07 The Regents Of The University Of California Orally available sEH/PDE4 dual inhibitors
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
JP2022535986A (ja) 2022-08-10
US20220098164A1 (en) 2022-03-31
WO2020249956A1 (fr) 2020-12-17
EP3983069A1 (fr) 2022-04-20
CN114269433A (zh) 2022-04-01
WO2020249956A9 (fr) 2022-03-03

Similar Documents

Publication Publication Date Title
IL277497A (en) Compounds for the treatment of Huntington's disease
IL271046A (en) Compounds for the treatment of Huntington's disease
IL279714A (en) Heteroaryl compounds for the treatment of Huntington's disease
IL275265A (en) Macrocyclic compounds for the treatment of disease
IL287945A (en) Compounds for the treatment of Huntington's disease
IL285782A (en) Compounds, compositions, and methods for treating disease
IL288958A (en) Exosomes for the treatment of diseases
IL288793A (en) Compounds for the treatment of respiratory diseases
IL290770A (en) Compounds and methods for treating oxalate-related diseases
GB201909468D0 (en) Compounds for treating cancer
PT3574912T (pt) Composição para tratamento de doença diabética
FI4021505T3 (fi) Lääke tartuntatautien hoitamiseksi
GB201917691D0 (en) Compounds for treating respiratory disease
GB201908451D0 (en) Compounds for treating respiratory disease
GB201908453D0 (en) Compounds for treating respiratory disease
GB201908885D0 (en) Therapeutic compounds
IL290319A (en) Compound for combined treatment
EP4058063A4 (fr) Méthodes de traitement de maladies
ZA202006126B (en) Compounds for treating alzheimer's disease
GB201911574D0 (en) Therapeutic compounds
GB201911580D0 (en) Therapeutic compounds
GB201907813D0 (en) Therapeutic compounds
GB201903597D0 (en) Therapeutic compounds
GB201903599D0 (en) Therapeutic compounds
GB201909466D0 (en) Compounds for treating cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)